Author

J. S. Gutkind

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9 Cell Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:cancer & tumor microenvironment· 7 Organism:human· 7 Research Focus:drug response / drug discovery· 6 Organism:mouse· 5 Research Focus:cell signaling & trafficking· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2

Frequent Co-Authors

Z. Wang· 6 shared V. H. Wu· 4 shared A. A. Molinolo· 3 shared M. M. Allevato· 3 shared A. Sharabi· 2 shared E. E. W. Cohen· 2 shared F. Faraji· 2 shared J. A. Califano· 2 shared

Activity by Year

2019-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

Z. Wang

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Structural and dynamic changes in P-Rex1 upon activation by PIP3 and inhibition by IP4

S. K. Ravala, S. R. Adame-Garcia, S. Li, C.-L. Chen, M. A. Cianfrocco, J. S. Gutkind, J. N. Cash, J. J. G. Tesmer

This study identifies structural changes in P-Rex1 upon activation by PIP3 and inhibition by IP4, revealing how these interactions regulate its GEF activity.

bioRxiv · Sep 15, 2023Biochemistry

A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC

Y. Goto, K. Koshizuka, T. Ando, H. Izumi, X. Wu, K. Ford, X. Feng, Z. Wang, N. Arang, M. M. Allevato, A. Kishore, P. Mali, J. S. Gutkind

This study identifies mTOR inhibition as a way to prevent adaptive resistance to CDK4/6 blockade in HNSCC by targeting cell cycle pathways.

bioRxiv · Aug 7, 2023Cancer Biology

YAP-Driven Oral Epithelial Stem Cell Malignant Reprogramming at Single Cell Resolution

F. Faraji, S. I. Ramirez, L. Clubb, K. Sato, V. Burghi, T. S. Hoang, A. Officer, P. Y. Anguiano Quiroz, W. M. Galloway, Z. Mikulski, K. Medetgul-Ernar, P. Marangoni, K. B. Jones, A. A. Molinolo, K. Kim, , J. S. Gutkind

The paper identifies YAP-driven reprogramming of oral epithelial stem cells into tumor-initiating cells using single-cell multiomics, revealing conserved transcriptional programs linked to poor patient survival.

bioRxiv · Jul 24, 2023Cancer Biology

Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity

A. E. Smith, S. Chan, Z. Wang, A. McCloskey, Q. Reilly, J. Z. Wang, H. V. Patel, K. Koshizuka, H. S. Soifer, L. Kessler, A. Dayoub, V. Villaflor, D. Adkins, J. Y. Bruce, A. Ho, , S. Malik

This study combines tipifarnib and alpelisib to target PI3K-mTOR and HRAS in HNSCC, showing synergy in mTOR inhibition and clinical potential for R/M HNSCC patients.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

A. Ruiz-Saenz, C. E. Atreya, C. Wang, B. Pan, C. A. Dreyer, D. Brunen, A. Prahallad, D. P. Munoz, D. J. Ramms, V. Burghi, D. S. Spassov, E. Fewings, Y. C. Hwang, C. Cowdrey, C. Moelders, , J.-P. Coppe

This study identifies a SRC-relayed COX2-inflammatory program that drives resistance to BRAF/MEK/EGFR therapies in BRAFV600E colorectal tumors and shows that co-targeting COX2 improves therapeutic outcomes.

bioRxiv · Oct 20, 2022 · PreprintCancer Biology

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

R. Saddawi-Konefka, A. O'Farrell, F. Faraji, L. Clubb, M. M. Allevato, N.-A. A. S. Anang, S. M. Jensen, Z. Wang, V. H. Wu, B. S. Yung, R. Al Msari, I. Franiak Pietryga, A. A. Molinolo, J. P. Mesirov, A. B. Simon, , J. S. Gutkind

This study shows that lymphatic-preserving treatment sequences enhance cDC1-dependent antitumor immunity in HNSCC by avoiding lymphablation, which compromises ICI response.

bioRxiv · Feb 1, 2022Cancer Biology

Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs

M. Gilardi, R. Saddawi-Konefka, V. H. Wu, M. A. Lopez-Ramirez, Z. Wang, F. Soto, D. J. Steffen, M. Proietto, Z. Mikulski, H. Miki, A. Sharabi, D. Kupor, R. Rueda, D. P. Hollern, J. Wang, J. S. Gutkind

This study demonstrates that microneedle-mediated local delivery of anti-CTLA-4 antibody reduces immune-related adverse events while effectively treating oral squamous cell carcinoma.

bioRxiv · Dec 7, 2021Cancer Biology

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

F. Haderk, C. Fernandez-Mendez, L. Cech, J. Yu, I. M. Meraz, V. Olivas, D. Barbosa Rabago, D. L. Kerr, C. Gomez, D. V. Allegakoen, J. Guan, K. N. Shah, K. A. Herrington, O. M. Gbenedio, S. Nanjo, , T. G. Bivona

This study identifies a FAK-YAP signaling axis that drives drug-tolerant persister cells and residual disease in lung cancer, showing that inhibiting this axis improves tumor response to targeted therapies.

bioRxiv · Oct 23, 2021Cancer Biology

Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response

M. Pagadala, V. H. Wu, E. Perez-Guijarro, H. Kim, A. Castro, J. Talwar, T. Sears, C. Gonzalez-Colin, S. Cao, B. Schmiedel, S. Goudarzi, D. Kirani, R. Salem, G. Morris, O. Harismendy, , H. Carter

The paper identifies germline variants associated with the tumor immune microenvironment, linking them to cancer risk and immunotherapy response.

bioRxiv · Apr 14, 2021 · PreprintCancer Biology

G protein-regulated endocytic trafficking of adenylyl cyclase type 9

A. M. Lazar, R. Irannejad, T. A. Baldwin, A. B. Sundaram, J. S. Gutkind, A. Inoue, C. W. Dessauer, M. Von Zastrow

This study shows AC9 traffics from the plasma membrane to endosomes via Gs, unlike AC1, and contributes to cAMP production from endosomes.

bioRxiv · Apr 23, 2020Cell Biology

Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4

Z. Wang, V. H. Wu, M. M. Allevato, M. Gilardi, Y. He, J. L. Callejas-Valera, L. Vitale-Cross, D. Martin, P. Amornphimoltham, J. Mcdermott, Y. Goto, A. A. Molinolo, A. B. Sharabi, E. E. W. Cohen, Q. Chen, , J. S. Gutkind

This paper develops a syngeneic mouse model of tobacco-associated HNSCC that shows high response rates to anti-CTLA-4 therapy.

bioRxiv · Jun 15, 2019 · PreprintCancer Biology

Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling

A. N. Stratman, O. M. Farrelly, C. M. Mikelis, M. F. Miller, Z. Wang, V. N. Pham, A. E. Davis, M. C. Burns, S. A. Pezoa, D. Castranova, T. M. Kilts, G. E. Davis, J. S. Gutkind, B. M. Weinstein

The paper shows that inhibiting phosphoinositide recycling in endothelial cells reduces tumor growth and angiogenesis by impairing VEGF signaling.

bioRxiv · Apr 18, 2019Cell Biology